skip to main content

SCLC — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

EasyLung CancerSCLCSCE Medical Oncology

A 65-year-old man with extensive-stage SCLC has completed 4 cycles of carboplatin-etoposide-atezolizumab with a partial response. What should the ongoing maintenance strategy be?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Continue atezolizumab maintenance until disease progression or unacceptable toxicity

After completion of induction carboplatin-etoposide-atezolizumab for ES-SCLC (NICE TA638, IMpower133), atezolizumab is continued as single-agent maintenance until disease progression or unacceptable toxicity. There is no role for maintenance chemotherapy. This maintenance strategy demonstrated the OS benefit seen in the trial.

Reference: NICE TA638 Atezolizumab with carboplatin and etoposide for ES-SCLC; IMpower133